Phase 2 Metastatic Head and Neck Squamous Cell Carcinoma Clinical Trials
9 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–9 of 9 trials
Recruiting
Phase 2
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Head and Neck Squamous Cell Carcinoma+22 more
National Cancer Institute (NCI)150 enrolled221 locationsNCT05136196
Recruiting
Phase 2Phase 3
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Bicara Therapeutics650 enrolled129 locationsNCT06788990
Recruiting
Phase 1Phase 2
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 2
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Metastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaClinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8+19 more
Emory University28 enrolled2 locationsNCT06636734
Recruiting
Phase 2
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Dan Zandberg15 enrolled1 locationNCT06052839
Recruiting
Phase 2
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
CarcinomaRecurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
NATCO Pharma Ltd.21 enrolled13 locationsNCT05283226
Recruiting
Phase 2
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 2
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello65 enrolled11 locationsNCT06856213
Recruiting
Phase 1Phase 2
A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab
Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Pancreatic CancerMetastatic Prostate Cancer
ImmunoGenesis71 enrolled1 locationNCT06782555